Q-omics provides the consensus-scored EIF3EP2 profile across patient tissues and cancer cell-line models. EIF3EP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF3EP2 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, EIF3EP2 RNA expression shows 6,438 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KICH, and STAD as cancer lineages where EIF3EP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3EP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3EP2 survival associations across molecular data types. EIF3EP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3EP2 RNA expression–survival associations across cancer types. High EIF3EP2 expression shows unfavorable associations in KIRC, KICH, UCS, THYM, ACC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF3EP2 RNA expression.
This table summarizes EIF3EP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3EP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3EP2 shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in LUAD. The KICH box plot shows higher EIF3EP2 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .039).
This table shows molecular features associated with EIF3EP2 in patient tissues and cancer cell lines. In patient samples, EIF3EP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
